Veronica Karpinski

Vaccine-induced spike- and nucleocapsid-specific cellular responses maintain potent cross-reactivity to SARS-CoV-2 Delta and Omicron variants

Anna M. Acosta, P. Frankel, J. Zaia, 2022, iScience.

Successful outcome of pre-engraftment COVID-19 in an HCT patient: impact of targeted therapies and cellular immunity

I. Aldoss, J. Zaia, S. Forman, 2022, Blood Advances.

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

P. Frankel, H. Andersen, D. Diamond, 2022, NPJ vaccines.

Synthetic multiantigen MVA vaccine COH04S1 protects against SARS-CoV-2 in Syrian hamsters and non-human primates

P. Frankel, H. Andersen, D. Diamond, 2021, npj Vaccines.

Safety and immunogenicity of a synthetic multiantigen modified vaccinia virus Ankara-based COVID-19 vaccine (COH04S1): an open-label and randomised, phase 1 trial

A. Sette, P. Frankel, J. Zaia, 2022, The Lancet Microbe.